Literature DB >> 20110344

Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response.

Adam E Gaweda1, Linda J Goldsmith, Michael E Brier, George R Aronoff.   

Abstract

BACKGROUND AND OBJECTIVES: The erythropoietic response in hemodialysis patients depends on several physiologic factors. Most epidemiologic studies include the effect of these factors by representing them as confounders. This study tested the hypothesis that iron stores, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism act as nonlinear effect modifiers of the erythropoietic response and quantified the magnitude of those effects over clinically relevant ranges. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The following retrospective data from 209 hemodialysis patients receiving Epoetin alfa (Epo) were collected: monthly: predialysis hemoglobin (Hgb), transferrin saturation, serum albumin, dialysis adequacy (Kt/V); quarterly: predialysis serum ferritin and intact parathyroid hormone over a period of 13 to 69 months. The study analyzed the dynamic relationship between hemoglobin and Epo, considering nonlinear effect modification by ferritin, transferrin saturation, Kt/V, albumin, and parathyroid hormone individually.
RESULTS: Maximum Hgb response to Epo was achieved for serum ferritin between 350 and 500 ng/ml, transferrin saturation greater than 30%, Kt/V greater than 1.4, and albumin greater than 3.8 g/dl. Hgb sensitivity to Epo decreases by about 30% as parathyroid hormone increases from 0 through 1000 pg/ml.
CONCLUSIONS: Serum ferritin, transferrin saturation, Kt/V, serum albumin, and intact parathyroid hormone are markers of nonlinear effect modification of the erythropoietic response in hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20110344      PMCID: PMC2849695          DOI: 10.2215/CJN.04710709

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  27 in total

1.  The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin.

Authors:  N Tessitore; G P Solero; G Lippi; A Bassi; G B Faccini; V Bedogna; L Gammaro; G Brocco; G Restivo; P Bernich; A Lupo; G Maschio
Journal:  Nephrol Dial Transplant       Date:  2001-07       Impact factor: 5.992

2.  Last observation carry-forward and last observation analysis.

Authors:  Jun Shao; Bob Zhong
Journal:  Stat Med       Date:  2003-08-15       Impact factor: 2.373

3.  Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients.

Authors:  Anatole Besarab; Neeta Amin; Muhammad Ahsan; Susan E Vogel; Gary Zazuwa; Stanley Frinak; James J Zazra; J V Anandan; Ajay Gupta
Journal:  J Am Soc Nephrol       Date:  2000-03       Impact factor: 10.121

4.  The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations.

Authors:  R M Baron; D A Kenny
Journal:  J Pers Soc Psychol       Date:  1986-12

5.  Erythropoietin requirements increase following hospitalization in end-stage renal disease patients.

Authors:  M S Yaqub; J Leiser; B A Molitoris
Journal:  Am J Nephrol       Date:  2001 Sep-Oct       Impact factor: 3.754

Review 6.  Resolving the paradigm crisis in intravenous iron and erythropoietin management.

Authors:  A Besarab
Journal:  Kidney Int Suppl       Date:  2006-05       Impact factor: 10.545

Review 7.  Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients.

Authors:  A Besarab; C L Dalton
Journal:  Nephrol Nurs J       Date:  2001-08       Impact factor: 0.959

8.  Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients.

Authors:  Kamyar Kalantar-Zadeh; Rudolph A Rodriguez; Michael H Humphreys
Journal:  Nephrol Dial Transplant       Date:  2004-01       Impact factor: 5.992

Review 9.  Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients.

Authors:  Tilman B Drüeke; Kai-Uwe Eckardt
Journal:  Nephrol Dial Transplant       Date:  2002       Impact factor: 5.992

10.  Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.

Authors:  Ezio Movilli; Giovanni C Cancarini; Valerio Vizzardi; Corrado Camerini; Giuliano Brunori; Silvia Cassamali; Rosario Maiorca
Journal:  J Nephrol       Date:  2003 Jul-Aug       Impact factor: 3.902

View more
  20 in total

1.  Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients.

Authors:  E Lars Penne; Neelke C van der Weerd; Muriel P C Grooteman; Albert H A Mazairac; Marinus A van den Dorpel; Menso J Nubé; Michiel L Bots; Renée Lévesque; Piet M ter Wee; Peter J Blankestijn
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 8.237

2.  Evaluation of the impact of a new synthetic vitamin E-bonded membrane on anemia and rHuEPO requirement in ESRD patients with central venous catheters: a pilot study.

Authors:  S Mandolfo; B Corradi; R Bucci; M Farina; F Pilolli; F Galli
Journal:  Int Urol Nephrol       Date:  2011-09-29       Impact factor: 2.370

Review 3.  The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.

Authors:  Nicolas Roberto Robles
Journal:  Clin Drug Investig       Date:  2016-06       Impact factor: 2.859

Review 4.  Markers of iron status in chronic kidney disease.

Authors:  Adam E Gaweda
Journal:  Hemodial Int       Date:  2017-03-22       Impact factor: 1.812

5.  The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.

Authors:  Junichi Ishigami; Tsuyoshi Onishi; Satomi Shikuma; Wataru Akita; Yoshihiro Mori; Tomoki Asai; Michio Kuwahara; Sei Sasaki; Yusuke Tsukamoto
Journal:  Clin Exp Nephrol       Date:  2012-07-03       Impact factor: 2.801

6.  The role of short daily hemodialysis in the control of hyperphosphatemia, secondary hyperparathyroidism and anemia.

Authors:  Jie-Long Jiang; Wei Ren; Yan Li; Guang-Yi Liu; Cai-Ping Zhou; Ke-Liang Su; Wei Chen; Ke Wang; Li-Jun Ni; Zhao Hu
Journal:  Int Urol Nephrol       Date:  2013-04-17       Impact factor: 2.370

7.  Impacts of parathyroidectomy on renal anemia and nutritional status of hemodialysis patients with secondary hyperparathyroidism.

Authors:  Chen Chen; Hua Wu; Lin Zhong; Xin Wang; Zhuang-Jie Xing; Bi-Hu Gao
Journal:  Int J Clin Exp Med       Date:  2015-06-15

8.  Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial.

Authors:  Jonathan Himmelfarb; T Alp Ikizler; Charles Ellis; Pingsheng Wu; Ayumi Shintani; Sanjay Dalal; Mark Kaplan; Michel Chonchol; Raymond M Hakim
Journal:  J Am Soc Nephrol       Date:  2013-12-26       Impact factor: 10.121

9.  Dosing of erythropoiesis-stimulating agents can be reduced by a new administration regimen.

Authors:  Bergur V Stefánsson; Börje Haraldsson; Ulf Nilsson
Journal:  Nephron Extra       Date:  2011-08-19

10.  Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry.

Authors:  Takayuki Hamano; Naohiko Fujii; Terumasa Hayashi; Hiroyasu Yamamoto; Kunitoshi Iseki; Yoshiharu Tsubakihara
Journal:  Kidney Int Suppl (2011)       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.